The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis. FE [Internet]. 2019 Jul. 10 [cited 2025 Oct. 29];20(1). Available from: https://journals.seedstm.com/index.php/FE/article/view/1435